Capabilities to transfer
Workflows, expertise and systems designed around your local institution.
- Programme feasibility
- Disease burden, eligible population and commercial modelling.
- Partner / hospital selection
- Matching capability to the clinical context.
- CD34+ HSPC workflow
- Mobilisation, collection, selection and processing.
- Lentiviral platform support
- Vector supply and qualification strategy.
- Regulatory pathway planning
- Dossier structure and submission preparation.
- Clinical trial design
- Protocol development and endpoint selection.
- Compassionate access
- Where the local framework permits named-patient access.
- Commercialisation strategy
- Reimbursement and sustainable delivery models.
What does your institution need first?
Begin with your existing infrastructure, clinical governance and local regulatory pathway. Feasibility establishes the programme requirements.
Discussion preparation
Your institutional baseline
Use these prerequisites to prepare a discussion. This checklist is not a clinical assessment or a determination of regulatory readiness.
0 of 4discussion prerequisites identified.
Connect the laboratory pathway with patient services.
For an autologous HSPC programme, the feasibility discussion should connect the proposed product and local manufacturing scope with collection, specialist clinical services and continuing follow-up. Distinguish a platform’s potential from the permissions, evidence and supply rights of the product being considered.
FDA regulates cellular and gene therapy products and maintains a list of specific approved products. A technology category or manufacturing capability should therefore be assessed separately from the status of a particular product.
FDA: Cellular & Gene Therapy ProductsExternal references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.
Questions for the programme brief
Which product can be accessed?
Confirm the construct or editing approach, proposed indication, technology rights and permitted local activities.
Which institutional interfaces matter?
Map collection, laboratory processing, quality review and specialist clinical responsibilities before sizing the programme.
What continues after transfer?
Review ongoing supply, change management, safety oversight and the responsibilities for maintaining the programme’s records.
What to prepare for review
- Product-access and intended-use brief
- Haematology and transplant-service baseline
- Facility, quality and follow-up ownership map
Working environments
Equipment and preparation for local capability.
Illustrative stock photography provides context for the people, processes and working environments behind this capability.
